Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG.

Clin Cancer Res. 2013 Mar 1;19(5):1244-56. doi: 10.1158/1078-0432.CCR-12-3149. Epub 2013 Feb 19.

2.

Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.

Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM.

Clin Cancer Res. 2005 Sep 1;11(17):6261-9.

3.
4.

Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.

Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, Yang CS, Chen Z', Shin DM.

Int J Cancer. 2008 Sep 1;123(5):1005-14. doi: 10.1002/ijc.23585.

5.

Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.

Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, Müller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM.

Cancer Prev Res (Phila). 2014 Mar;7(3):283-91. doi: 10.1158/1940-6207.CAPR-13-0215. Epub 2013 Oct 3.

6.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

7.

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM.

Clin Cancer Res. 2009 Mar 1;15(5):1585-92. doi: 10.1158/1078-0432.CCR-08-2068. Epub 2009 Feb 3.

8.

Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR.

Clin Cancer Res. 2010 May 1;16(9):2571-9. doi: 10.1158/1078-0432.CCR-10-0333. Epub 2010 Apr 13.

9.

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.

PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.

10.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

12.

Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F.

Clin Cancer Res. 2005 Feb 1;11(3):1268-76.

13.

Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.

Zhao Y, Hao Y, Ji H, Fang Y, Guo Y, Sha W, Zhou Y, Pang X, Southerland WM, Califano JA, Gu X.

Cancer Prev Res (Phila). 2010 Jun;3(6):787-96. doi: 10.1158/1940-6207.CAPR-09-0243. Epub 2010 May 25.

14.

Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.

Mu XY, Dong XL, Sun J, Ni YH, Dong Z, Li XL, Sun EL, Yi Z, Li G.

Asian Pac J Cancer Prev. 2014;15(1):69-73.

15.

Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.

Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, Sarkar FH.

J Cell Biochem. 2010 May;110(1):171-81. doi: 10.1002/jcb.22523. Retraction in: J Cell Biochem. 2016 Aug;117(8):1961.

16.
18.
19.

Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.

Xie X, Ghadimi MP, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D.

Clin Cancer Res. 2011 Sep 15;17(18):5901-12. doi: 10.1158/1078-0432.CCR-11-0660. Epub 2011 Aug 5.

20.

Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.

Lin C, Lu W, Ren Z, Tang Y, Zhang C, Yang R, Chen Y, Cao W, Wang L, Wang X, Ji T.

Cancer Lett. 2016 Jul 10;377(1):1-10. doi: 10.1016/j.canlet.2016.04.023. Epub 2016 Apr 18.

PMID:
27090738

Supplemental Content

Support Center